LMT-28 is an orally active and the first synthetic IL-6 inhibitor. That functions through direct binding to gp130. LMT-28 displays low toxicity and selectively inhibits IL-6–induced phosphorylation of STAT3, JAK2, and gp130.

LMT-28 decreases IL-6-induced luciferase activity by ~90% at a concentration of 50 μM and exhibits (IC50: 5.9 μM). LMT-28 (1-100 μM; 1 hour) selectively inhibits IL-6-induced phosphorylation of STAT3, JAK2, and gp130. LMT-28 (1-10 μM; 72 hours) inhibits IL-6-induced proliferation of the human erythroleukemic cell line TF-1 .

LMT-28 (0.25 or 1 mg/kg; p.o.) ameliorates the progression of pancreatitis in mice. LMT-28 (0-0.5 mg/kg; p.o.; once daily for 15 days) alleviates CIA in mice. LMT-28 binds directly and specifically to gp130, and thereby inhibits the interaction of gp130 with the IL-6/IL-6Rα complex .

1239600-18-0

C17H29NO4

311.42

LMT-28

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years